Tenax Therapeutics is focused on providing valuable pharmaceutical products that address conditions with significant unmet medical needs.
Focus on InnovationOur strategy is to create value for patients, providers, and ultimately shareholders, by focusing on innovative pharmaceutical products that meet the following criteria:
- Treat a condition with few or no approved therapies
- Significantly improve outcomes
- Potential for efficient clinical development and expedited regulatory pathway to approval
Jan 16 2018 Tenax Therapeutics Announces Plan to Develop Levosimendan for a Pulmonary Hypertension Indication with No FDA Approved Therapies Jul 28 2017 Tenax Therapeutics Provides Regulatory Update on Levosimendan May 16 2017 Tenax Meets with FDA to Discuss Positive Mortality Data and Potential Levosimendan NDA Submission